Xinjiang medical university | China

AUTHOR PROFILE

🎓EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University | China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun He’s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

📊🔬Notable Publication:

Utilizing Metagenomic Next-Generation Sequencing (mNGS) for Rapid Pathogen Identification and to Inform Clinical Decision-Making: Results from a Large Real-World Cohort

- Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
- Journal: Infectious Diseases and Therapy
- Year: 2023

Use of Next-Generation Sequencing to Detect Polymorphism of 11 HLA Allele Loci in the Chinese Han Population and Variance from Other Common and Well-Documented Lists

- Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
- Journal: HLA
- Year: 2023

Posttransplant de novo DSA and NDSA Affect GvHD, OS, and DFS after Haplo-HSCT in Patients Without Pre-existing HLA Antibodies of Hematological Malignancies

- Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
- Journal: Frontiers in Immunology
- Year: 2022

Splenic Irradiation Combined with Plasmapheresis and Rituximab: A New Option Reducing Donor-Specific Antibody in Haploidentical Hematopoietic Stem Cell Transplantation

- Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
- Journal: Bone Marrow Transplantation
- Year: 2023

Role of Lipid Metabolism in Hepatocellular Carcinoma

- Authors: Cheng, Y., He, J., Zuo, B., He, Y.
- Journal: Discover Oncology
- Year: 2024